证券代码：832982 证券简称：锦波生物 公告编号：2025-136 山西锦波生物医药股份有限公司 第四届监事会第九次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 监事汤莉因出差以通讯方式参与表决。 二、议案审议情况 根据《中华人民共和国公司法》《上市公司章程指引（2025 年修订）》以及 《北京证券交易所股票上市规则》等相关法律法规、规范性文件的规定，结合公 （一）会议召开情况 1.会议召开时间：2025 年 8 月 19 日 2.会议召开地点：公司二楼会议室 3.会议召开方式：现场加通讯 4.发出监事会会议通知的时间和方式：2025 年 8 月 14 日以电话方式发出 5.会议主持人：监事会主席汤莉女士 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 （一）审议通过《关 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-135 山西锦波生物医药股份有限公司 第四届董事会第十四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 8 月 19 日 2.会议召开地点：公司二楼会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2025 年 8 月 16 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：汤莉、于玉凤、何振瑞、薛芳琴、兰小宾 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事金雪坤、王玲玲、张金鑫、阎丽明、梁桐栋因出差或外地办公以通讯方 式参与表决。 二、议案审议情况 （一）审议通过《关于取消监事会、修订<公司章程>并办理工商变更登 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong potential for stock price appreciation in the next six months [7]. Core Insights - The company achieved a revenue of 859 million yuan in H1 2025, representing a year-on-year increase of 42.43%. The net profit attributable to the parent company was 392 million yuan, up 26.65% [1][2]. - The growth in revenue is driven by strong performance in both medical devices and skincare products, with notable contributions from proprietary brands [2]. - The company has increased its marketing and R&D expenditures, leading to a rise in expense ratios, which has temporarily affected net profit margins [3]. - The introduction of new products, particularly in the recombinant collagen segment, is expected to enhance revenue growth in the future [4]. Financial Summary - For H1 2025, the company reported a gross margin of 90.68%, with a net profit margin of 45.66%. The gross margin remained stable, while the net profit margin declined due to increased expenses [3]. - Revenue projections for 2025-2027 are estimated at 2.177 billion yuan, 2.887 billion yuan, and 3.695 billion yuan, respectively, with net profits expected to reach 1.062 billion yuan, 1.433 billion yuan, and 1.865 billion yuan [4][5]. - The company’s earnings per share (EPS) is projected to grow from 9.23 yuan in 2025 to 16.21 yuan in 2027, reflecting strong growth potential [5]. Product and Market Position - The company is the only approved provider of recombinant collagen implants in the market, which is expected to enhance its market penetration [4]. - The skincare segment, particularly functional skincare products, has shown rapid growth, contributing significantly to overall revenue [2]. Expense and Profitability Analysis - The expense ratio for H1 2025 was 34.87%, with a notable increase in sales and R&D expenses. The sales expense ratio was 21.05%, reflecting increased marketing efforts [3]. - Despite the rise in expenses, the company maintains a high gross margin, indicating strong pricing power and operational efficiency [3].

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 688363 华熙生物 | 790.73万 | 1.15% | 180.80万 | 0.26% | -971.53万 | -1.42% | | 000615 *ST美谷 | -310.33万 | -9.17% | 266.28万 | 7.87% | 44.05万 | 1.30% | | 300896 爱美客 | -434.66万 | -0.43% | 366.59万 | 0.37% | 68.07万 | 0.07% | 证券之星消息，8月21日医疗美容板块较上一交易日上涨1.37%，锦波生物领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流入45.74万元，游资资金净流入813.67万元，散户资 金净流出859.41万元。医疗 ...

Group 1 - The beauty and personal care concept stocks experienced significant fluctuations, with Jieya Co., Ltd. and Shuiyang Co., Ltd. rising over 10% [1] - Huaye Fragrance and Huaxi Biotechnology increased by more than 5% [1] - Lafang Home Products, Jinbo Biotechnology, and Zhongshun Jierou saw gains of over 3% [1]

北交所公司上半年分红预案一览 | | | 预案公布 | 每10股派 | 每10股送 | 预案公布次 | 预案公布后 | 派现金 | 派现占净利 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 代码 | 简称 | 日 | 现（元） | 转（股） | 日涨跌 | 涨跌（%） | 额(万元) | 润比例 | | | | | | | （%） | | | （%） | | 832982 | 锦波 生物 | 2025.08.11 | 10 | | -5.33 | -2.23 | 11506.53 | 29.35 | | 837663 | 明阳 科技 | 2025.08.15 | 2.246307 | | 2.03 | 2.11 | 3000.00 | 94.10 | | 873726 | 卓兆 点胶 | 2025.08.11 | 2.2 | | 7.70 | 60.96 | 1805.70 | 67.42 | | 837242 | 建邦 科技 | 2025.08.12 | 2 | | -2.82 | 13.13 | 1316.48 | 26.65 | ...

证券之星消息，8月20日医疗美容板块较上一交易日上涨3.29%，爱美客领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 188.50 | 3.96% | 6.60万 | | 12.23 Z | | 688363 | 华熙生物 | 55.17 | 2.53% | 6.35万 | | 3.46 Z | | 000615 | *ST美谷 | 3.29 | 0.92% | 8.81万 | | 2891.00万 | | 832982 | 锦波生物 | 312.89 | -0.66% | 8461.09 | | 2.65亿 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流入7610.08万元，游资资金净流入 ...

证券之星消息，8月19日医疗美容板块较上一交易日下跌0.76%，爱美客领跌。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 832982 | 锦波生物 | 314.96 | 2.11% | 1.44万 | 4.53 乙 | | 000615 | *ST美谷 | 3.26 | 1.56% | 12.18万 | 3954.31万 | | 688363 | 华熙生物 | 53.81 | -0.06% | 3.32万 | 1.79亿 | | 300896 | 爱美客 | 181.32 | -1.39% | 4.85万 | 8.80亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出762.74万元，游资资金净流入884.18万元，散户资 金净流出121.45万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 │主力净流入（元）│主力净占比│游资净流入（元） ...

Group 1 - The core conclusion of the report on Lens Technology (300433.SZ) indicates a new growth phase driven by multiple engines in the consumer electronics sector, with projected revenues of CNY 921.8 billion, CNY 1155.1 billion, and CNY 1377.9 billion for 2025-2027, representing year-on-year growth of 31.9%, 25.3%, and 19.3% respectively, and net profits of CNY 52.7 billion, CNY 65.0 billion, and CNY 78.3 billion, with year-on-year growth of 45.3%, 23.5%, and 20.4% [1][8] - The report highlights Lens Technology's deep moat in glass cover production, its strategic expansion into metal structural components, and its positioning in emerging markets such as AI hardware and smart automotive applications, which are expected to contribute significantly to revenue growth [9][8] - The report on Longda Co., Ltd. (688231.SH) emphasizes its focus on high-temperature alloys and the increasing demand from the aerospace and gas turbine sectors, projecting revenues of CNY 17.6 billion, CNY 22.1 billion, and CNY 27.4 billion for 2025-2027, with net profits of CNY 1.2 billion, CNY 1.7 billion, and CNY 2.5 billion, reflecting growth rates of 74%, 51%, and 42% respectively [11][12] Group 2 - The report on Shengnong Development (002299.SZ) indicates a significant increase in net profit by 791.93% year-on-year for the first half of 2025, with revenues of CNY 88.56 billion and net profits of CNY 9.10 billion, despite a decline in chicken prices affecting revenue growth [14][15] - The report notes that Shengnong Development has improved its operational efficiency through breeding and cost reduction strategies, leading to a notable increase in profit margins, with a gross margin of 11.97% for the first half of 2025, up 2.73 percentage points year-on-year [15][16] - The report on Best (300580.SZ) highlights steady growth in its core turbocharger components business and successful expansion into new energy vehicle parts, with projected revenues of CNY 16.49 billion, CNY 20.20 billion, and CNY 23.74 billion for 2025-2027, and net profits of CNY 3.51 billion, CNY 4.19 billion, and CNY 5.02 billion [19][20]

Market Performance - The medical beauty sector increased by 1.03% on August 18, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3728.03, up 0.85%, while the Shenzhen Component Index closed at 11835.57, up 1.73% [1] Individual Stock Performance - Jinbo Biological (832982) closed at 308.46, with a rise of 3.60% and a trading volume of 16,000 shares [1] - Aimeike (300896) closed at 183.87, up 1.09% with a trading volume of 43,400 shares [1] - Huaxi Biological (688363) closed at 53.84, increasing by 1.01% with a trading volume of 49,300 shares [1] - *ST Meigu (000615) closed at 3.21, up 0.31% with a trading volume of 107,200 shares [1] Capital Flow Analysis - The medical beauty sector experienced a net outflow of 7.81 million yuan from main funds, while retail funds saw a net outflow of 22.98 million yuan [1] - Speculative funds had a net inflow of 30.79 million yuan [1] Detailed Capital Flow for Individual Stocks - Aimeike (300896) had a main fund net inflow of 15.99 million yuan, with a retail net outflow of 34.19 million yuan [2] - *ST Meigu (000615) saw a main fund net inflow of 0.25 million yuan, with a retail net outflow of 1.13 million yuan [2] - Huaxi Biological (688363) experienced a main fund net outflow of 24.06 million yuan, while retail funds had a net inflow of 1.23 million yuan [2]